| 货号 | HW484046 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | JM1-24-3 |
|---|
| 生物活性 | JM1-24-3 (0.001-10 ug/mL) binds dose-dependently to live A375, A2058, and WM266-4 melanoma cells, with significantly stronger binding to highly metastatic A2058 and WM266-4 cells than to low metastatic A375 cells [1]. JM1-24-3 (0.001-10 ug/mL) binds dose-dependently to A375, A2058, and WM266-4 melanoma cell lysates, with significantly stronger binding to highly metastatic A2058 cell lysates than to WM266-4 or low metastatic A375 cell lysates [1]. JM1-24-3 binds to recombinant MUC18 with a high affinity (K D = 1.60E-09) [1]. JM1-24-3 (0.001-1 ug/mL) binding to WM266-4 melanoma cells is partially dependent on N-linked glycosylation of MUC18, as tunicamycin treatment (3.0 ug/mL; 24 h) reduces binding by 40.7% [1]. JM1-24-3 (1 h, 6 h for RPPA; 0.5-24 h for WB) binding to MUC18 on WM266-4 melanoma cells modulates downstream signaling pathways, including time-dependent reduction of p-AKT (Ser473) and p-mTOR (Ser2448) phosphorylation, and alters expression of key cancer-associated proteins [1]. JM1-24-3 (150 ug/mL; 7 days) inhibits proliferation of A375, A2058, and WM266-4 melanoma cells by 52%, 76%, and 46% respectively after 7 days of incubation [1]. JM1-24-3 (150 ug/mL; 24 h) inhibits migration of WM266-4 melanoma cells by 58% after 24 h of incubation [1]. JM1-24-3 (150 ug/mL) inhibits invasion of WM266-4 melanoma cells by 52% [1]. Cell Proliferation Assay [1] Cell Line: A375, A2058, WM266-4 Concentration: 150 ug/mL Incubation Time: 7 days Result: Significantly inhibited proliferation of all three cell lines: A375 by 52%, A2058 by 76%, and WM266-4 by 46% (p < 0.01 for all) compared to irrelevant mAb treatment. Cell Migration Assay [1] Cell Line: WM266-4 Concentration: 150 ug/mL Incubation Time: 24 h Result: Significantly reduced WM266-4 cell migration by 58% (p < 0.01) compared to irrelevant mAb treatment. JM1-24-3 (6 mg/kg; i.p.; twice weekly; for 45 days) significantly reduces the volume of subcutaneous melanoma xenografts, with no observed toxicity [1]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 克隆类型 | Monoclonal |
|---|
| 靶标 | CD146, Melanoma cell adhesion molecule, S-endo 1 endothelial-associated antigen, Melanoma-associated antigen A32, MUC18, MCAM, Melanoma-associated antigen MUC18, Cell surface glycoprotein MUC18, Cell surface glycoprotein P1H12 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | P43121 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | JM1-24-3 |
|---|
| 背景 | Cell surface glycoprotein MUC18 (CD146/MCAM) is a ~71 kDa protein. Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as a surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration. |
|---|
| 文献 | 1. Feng R, et al. Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma. J Exp Clin Cancer Res. 2020;39(1):273. Published 2020 Dec 5. [HW484046]
2. Zhang F, et al. MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma. J Transl Med. 2025;23(1):473. Published 2025 Apr 24. [HW484046] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
